Side effects of bone-targeted therapies in advanced XXXX .

@entity1 @entity3747 @entity8 @entity171 @entity0 @entity460 @entity1011 @entity4381 @entity560 @entity2530
In up to 75% of cases, advanced @entity0 @entity1 eventually develop bone metastases with often debilitating skeletal-related events (SREs). Osteoclast inhibitors are commonly used as therapeutic mainstay with clinical studies showing superiority of denosumab over @entity171 (e.g., @entity4381 ) for the prevention of SREs. The present review discusses the adverse event profile of these agents, and addresses the prevention and management of untoward side effects. Adverse events associated with osteoclast inhibitors comprise @entity2530 of the jaw and @entity3747 . @entity3747 is more common with denosumab, particularly in severe @entity8 . During therapy, the appropriate prevention of these adverse events includes close attention to dental health, avoidance of invasive dental procedures, supplementation with @entity460 and @entity560 unless @entity1 are hypercalcemic, and regular monitoring of relevant serum values. Relating to the risk of nephrotoxicity, @entity171 but not denosumab have been incriminated. Therefore, serum @entity1011 levels should be checked prior to each dose of @entity4381 , and in severe @entity8 ( @entity1011 clearance < 30 ml/min) @entity4381 is contraindicated anyway. Acute-phase reactions are particularly linked to @entity171 . Consequently, if these adverse events predominate, switching to denosumab is recommended.
